Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 3Prostatic Neoplasms 2Stomach Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Liver Neoplasms 1Leukemia, Hairy Cell 1Inflammatory Breast Neoplasms 1Fibrosis 1Esophageal Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Hepatocellular 1Carcinoma, Ductal, Breast 1Breast Carcinoma In Situ 1

Interventions

Doxorubicin 8Cisplatin 5Chemotherapy, Adjuvant 5Thalidomide 4Radiofrequency Ablation 4Neoadjuvant Therapy 4Melphalan 4Cyclophosphamide 4Carboplatin 4tremelimumab 3fludarabine 3aldesleukin 3Sorafenib 3Irinotecan 3Capecitabine 3durvalumab 2carotuximab 2Temozolomide 2Tamoxifen 2Oxaliplatin 2Leucovorin 2Gemcitabine 2Fluorouracil 2Fluorodeoxyglucose F18 2Epirubicin 2Cryosurgery 2Biopsy 2Bevacizumab 2sargramostim 1ropidoxuridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Liver Neoplasms × High-Energy Shock Waves × Clear all
NCT00019604 2017-02-03

Radiofrequency Ablation in Treating Patients With Unresectable Primary or Metastatic Liver Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
44 enrolled 7 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡